Stocksigma LogoStocksigma Logo

Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion

Aarti Drugs delivered robust Q2 FY27 performance, with total revenue rising 27% YoY to Rs 828.8 crore and net profit jumping 83% YoY to Rs 82.8 crore

Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion

Aarti Drugs Ltd 路 Investor Presentation 路 04 Nov 2026, 3:17 am

Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion Aarti Drugs delivered robust Q2 FY27 performance, with total revenue rising 27% YoY to Rs 828.8 crore and net profit jumping 83% YoY to Rs 82.8 crore. EBITDA grew 63% YoY to Rs 137.9 crore, with margins expanding 370 bps YoY to a multi-year high of 16.6%, aided by higher realizations and backward integration at the Sayakha facility. Formulations and Specialty Chemicals drove broad-based growth. Ongoing brownfield expansions across anti-diabetic and anti-inflammatory segments remain on track to deepen penetration in regulated markets.

Original exchange filing (PDF)

More announcements from Aarti Drugs Ltd

All Aarti Drugs Ltd announcements